Eurizon Capital SGR S.p.A. Makes New $3.31 Million Investment in Natera, Inc. $NTRA

Eurizon Capital SGR S.p.A. bought a new stake in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,459 shares of the medical research company’s stock, valued at approximately $3,313,000.

Other large investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new stake in Natera in the fourth quarter valued at approximately $41,000. Horizon Investments LLC purchased a new stake in Natera during the third quarter valued at about $32,000. TD Waterhouse Canada Inc. purchased a new stake in Natera during the fourth quarter valued at about $62,000. Sound Income Strategies LLC grew its stake in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares in the last quarter. Finally, Fifth Third Bancorp grew its stake in Natera by 123.4% in the 4th quarter. Fifth Third Bancorp now owns 324 shares of the medical research company’s stock valued at $74,000 after buying an additional 179 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 1,688 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the sale, the insider owned 187,511 shares in the company, valued at approximately $38,270,995.10. This represents a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider directly owned 142,295 shares in the company, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 34,406 shares of company stock valued at $6,984,955 in the last quarter. Insiders own 5.05% of the company’s stock.

Natera Stock Down 2.0%

NASDAQ:NTRA opened at $218.81 on Tuesday. The business’s 50-day simple moving average is $202.69 and its two-hundred day simple moving average is $215.84. The stock has a market cap of $31.34 billion, a PE ratio of -134.24 and a beta of 1.56. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of analyst reports. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley reduced their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Piper Sandler restated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Finally, Wells Fargo & Company boosted their target price on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $256.60.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.